5PSQ-114 Adalimumab in patients with immune-mediated diseases: evaluating the transition to the biosimilar and patient-reported outcome measures (PROM)

<h3>Background and Importance</h3> The introduction of biosimilars in treatment of immuno-mediated diseases benefits both healthcare systems and patients. Nevertheless, patient concerns about switching may affect adherence and long-term outcomes. <h3>Aim and Objectives</h3> Assess how patients perceive the switch from reference to biosimilar or between biosimilars. <h3>Material and Methods</h3> Observational longitudinal study where patients switching from Humira or Hyrimoz to Yuflyma complete surveys before and after to assess parameters such as self-administration ability, pain level and their impact, satisfaction rate, patient-reported improvement after switch and the underlying reason for it. Pain, improvement and satisfaction were rated on a 0to5 scale. <h3>Results</h3> 55 patients were included(mean age46±12, 60%women). The pre-switch survey was answered by 55 patients;58.2% treated with Hyrimoz and 41.9% with Humira . The most common diagnoses were Crohn’s disease(34.0%), Hidradenitis suppurativa(14.5%) and rheumatoid arthritis(9.1%). While 80% were able to self-administer it, 10.8% of patients required assistance. Pain was reported by 58.2% of patients on reference. Only 25.5% rated it at level 0, 14.5% at 1, 20.0% at 2, 18.2% at 3, 16.4% at 4 and 5.5% at the highest level. Pain was a challenge to continuing the treatment, a source of anxiety for 11.0% and reason to need assistance for 5.5%. Satisfaction with reference was rated at level 3 or lower for 25.5%, 4 by 25.5% and 5 by 49.0%. After switching to Yuflma, 40 patients completed the survey, 97.5% could self-administer, and 2.5% needed assistance. Sixty percent noticed a change in pain perception, 65.0% reported no pain, 12.5% rated it at level 1, 20.0% at 2 and 2.5% at 3. None found it a challenge for treatment. As for the improvement, 52.1% rated at level 5, 22.5% at 4, 7.5% at 3, 12.5% at 2 and 5.0% at 1 or lower. This was due to being less painful and easier for 30.0% and anxiety feelings decreased for 20.0%. Satisfaction level was rated at level 5 for 80.0%, 7.5% rated it at 3 and 4 and 2.5% at 2 and 0. <h3>Conclusion and Relevance</h3> Switching to the biosimilar improved PROM, with most patients self-administering treatment, experiencing less pain, and greater satisfaction. However, not all patients participated in the follow-up, limiting comparisons between groups. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest